Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. FDX
3. CBRS
4. USO
5. SPY
6. MU
7. KBH
8. HTZ
9. HON
10. JPM

Go back to Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals (ALNY) PT Lowered to $160 at BMO Capital

February 8, 2018 12:41 PM EST

BMO Capital lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $160.00 (from $165.00) while maintaining an Outperform rating.

Analyst Do Kim commented, "Alnylam reported 4Q17 GAAP EPS of ($1.48), below our ($1.28) estimate and Street's ($1.38). The wider loss was driven by higher expenses due to... More